Clinical Trials · NCT05613387

A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

CompletedPhase 1Petrelintide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Zealand Pharma
Enrollment
68
Start date
Nov 2022
Locations
1 site, Germany
Primary endpoint
Incidence of treatment emergent adverse events (TEAEs)
View Petrelintide compound reference